Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioTech Holdings

www.biotechltd.com

Latest From BioTech Holdings

STOCKWATCH: Gilead damned for doing the right thing

The last thing you need on a Friday afternoon is for one of your biotech holdings to open the trading session down by more than 7%. And as the company in question was the large capitalization and profitable antiviral specialist Gilead Sciences, I did wonder if a new global conflict rather than a Ukrainian ceasefire had just been announced. But in this case, the news that took Gilead's share price down was entirely of its own making and, even worse, the reaction was in response to Gilead's best of intentions.

Pakistan

STOCKWATCH: Missing the point

As investors in life science stocks, and biotechnology companies in particular, suffered another week of significant losses there are still voices of denial from the analyst community that have completely missed the point of what the market is telling them. The generalist investor is selling out of biotech and nothing can stop the exit.

Infectious Diseases Cancer

PharmaRoth Looks Abroad With Type 2 Diabetes Product After NDI Notification Decision

FDA decides Sucanon is an investigational new drug, not a dietary ingredient, in response to PharmaRoth Labs’ NDI notification. The firm expected to sell Sucanon as a consumer health supplement via infomercials with no claims, but faces substantially higher costs on the IND pathway to market.

Consumer BioPharmaceutical

PharmaRoth Looks Abroad With Type 2 Diabetes Product After NDI Notification Decision

FDA decides Sucanon is an investigational new drug, not a dietary ingredient, in response to PharmaRoth Labs’ NDI notification. The firm expected to sell Sucanon as a consumer health supplement via infomercials with no claims, but faces substantially higher costs on the IND pathway to market.

Consumer BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register